← Back to home

ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA

Clinical trials for ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA trials appear

Sign up with your email to follow new studies for ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for men suffering debilitating hot flashes from cancer treatment

Symptom relief Recruiting now

This study is testing whether a medication called fezolinetant can safely reduce the frequency and severity of hot flashes in men with prostate cancer who are undergoing hormone-blocking therapy. Researchers will compare the drug to a placebo in 60 participants over 4 weeks to se…

Matched conditions: ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA

Phase: PHASE2 • Sponsor: Shehzad Basaria, M.D. • Aim: Symptom relief

Last updated Mar 27, 2026 12:38 UTC

ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA

Get alerted when new ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA trials appear

New hope for men suffering debilitating hot flashes from cancer treatment